Pain reduction and adverse effects of intravenous metoclopramide for acute migraine attack: A systematic review and meta-analysis of randomized-controlled trials

doi:10.5662/wjm.v12.i4.319

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 4

This Article

(152)

(165)

(0)

(8)

(4777)

(6)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Methodology

ISSN

2222-0682

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Meta-Analysis

World J Methodol. Jul 20, 2022; 12(4): 319-330
Published online Jul 20, 2022. doi: 10.5662/wjm.v12.i4.319

Full Size Figure Download Figure

Figure 4 Forest plot comparing pain reduction at 60 min between intravenous metoclopramide and other drugs. CI: Confidence interval; IV: Intravenous; SC: Subcutaneous.

Citation: Ungrungseesopon N, Wongtanasarasin W. Pain reduction and adverse effects of intravenous metoclopramide for acute migraine attack: A systematic review and meta-analysis of randomized-controlled trials. World J Methodol 2022; 12(4): 319-330
URL: https://www.wjgnet.com/2222-0682/full/v12/i4/319.htm
DOI: https://dx.doi.org/10.5662/wjm.v12.i4.319

Ungrungseesopon N, Wongtanasarasin W. Pain reduction and adverse effects of intravenous metoclopramide for acute migraine attack: A systematic review and meta-analysis of randomized-controlled trials. World J Methodol 2022; 12(4): 319-330 [PMID: 36159095 DOI: 10.5662/wjm.v12.i4.319]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.